Early Phase 1 Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
General requirements (all participants):
- Adults between 18 and 60 years old
- Body mass index (a measure of weight relative to height) between 18 and 28
- Weight of at least 50 kg
For people with Type 1 Diabetes (T1DM):
- Has had Type 1 diabetes for between 1 and 30 years
- Has an HbA1c (a blood sugar average over roughly 3 months) between 5.7% and 7.5%
- Is currently using an automated insulin delivery system (such as a closed-loop insulin pump)
For people with GCK-MODY (a specific inherited form of diabetes):
- Has an HbA1c between 5.7% and 7.5%
- Has had genetic testing that confirms a GCK gene change linked to this condition
For control participants (people without diabetes):
- Has an HbA1c below 5.5%
Who may not be able to join:
- People who have had one or more severe low blood sugar episodes in the past 3 months
- People who have been admitted to hospital for a serious diabetes-related complication called diabetic ketoacidosis in the past 6 months
- People with high blood pressure readings above certain levels (confirm with trial site)
- People whose kidneys are not filtering at a sufficient level, as measured by a blood test (confirm with trial site)
- People with elevated liver enzyme levels above a certain threshold, as measured by blood tests (confirm with trial site)
- People with a low red blood cell level (below a certain percentage) as measured by a blood test (confirm with trial site)
- People who have taken antioxidant vitamin supplements within 2 weeks before the study
- People currently taking steroid medications (such as cortisone or prednisone) that affect the whole body
- People currently taking antipsychotic medications
- People taking certain blood pressure medications, specifically atenolol, metoprolol, or propranolol
- People taking niacin (a form of vitamin B3 sometimes used for cholesterol)
- People taking a type of fluid tablet called a thiazide diuretic
- People taking an oral contraceptive pill containing more than 35 micrograms of ethinyl estradiol
- People currently taking growth hormone
- People taking immunosuppressant medications (medicines that reduce the immune system's activity)
- People taking any blood pressure-lowering medication
- People taking any cholesterol-lowering medication
- People who are pregnant
- People who have not yet reached full physical maturity (confirm with trial site)
- Women who are peri-menopausal or post-menopausal
- People who currently smoke
Additional exclusions for Type 1 Diabetes participants only:
- People taking any diabetes medication other than insulin
- People whose fasting C-peptide level (a marker of the body's own insulin production) is above 0.7 ng/mL (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel J Moore, MD, PhD, Vanderbilt University Medical Center
Phone: 615-322-7427
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Aim 1: Tissue glucose disposal (TGD); Aim 2: Nitric Oxide (NO) bioavailability
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.